It is a non-motile aerobicbacillus with a non-sporulated capsule measuring 0.5 to 2.0 μm.[3][4] It is biochemically characterised by being as catalase-positive, phenylalanine deaminase-negative, citrate test-positive, and urease-positive.[5] Among its virulence factors are its capsule, endotoxins, siderophores, antimicrobial resistance and antigenic phase variation.[6]
Incubation period
The incubation period lasts around 50 days, may vary between 1 and 12 weeks.[7]
Thanks to the recognition as a public health problem and appropriate control measures such as the implementation of better health service provisions, the incidence of this microorganism in countries such as Papua New Guinea, South Africa, India and the Caribbean has decreased significantly.[8]
References
^Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. p. 370. ISBN978-0-8385-8529-0.
^Mesia JM, Jáuregui JS, Arias PP (May 2007). "Donovanosis, case report"(PDF). Revista Mexicana de Coloproctologí. 13: 59–65 – via medigraphic Artemisa en lÌnea.
^Dorado JS, Montes JO, Espinar CP, Ezcurra MM (2014-03-01). "Protocolo diagnóstico y terapéutico de las úlceras genitales" [Diagnostic and therapeutic protocol of genital ulcers]. Medicine - Programa de Formación Médica Continuada Acreditado. Enfermedades infecciosas (III): Infecciones por espiroquetas, borrelias, chlamydias y micoplasmas (in Spanish). 11 (51): 3024–3028. doi:10.1016/S0304-5412(14)70733-4.
^ abDixit P, Kotra LP (January 2007). "Calymmatobacterium Granulomatis Infections". In Enna SJ, Kotra LP, Bylund DB (eds.). xPharm: The Comprehensive Pharmacology Reference. Elsevier. pp. 1–4. doi:10.1016/b978-008055232-3.60880-3. ISBN978-0-08-055232-3.